Cardiotoxicity of Immune Checkpoint Inhibitors

Дата публикации: 01-10-2024 00:00:00

This systematic review and meta-analysis updates data on the incidence of cardiovascular adverse events in clinical trials of immune checkpoint inhibitors alone and in combination therapies and provides recommendations for management among patients treated for cancer.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Neoadjuvant Immune Checkpoint Inhibitors in Early Breast Cancer	0	7.64	01-10-2024
2	Troponin Screening and Major Cardiovascular Adverse Events During ICI Therapy	0	7.02	21-07-2026
3	Immune Checkpoint Inhibitors for Child-Pugh B Hepatocellular Carcinoma	0	11.22	01-10-2023
4	Checkpoint Inhibitors Plus Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors	0	4.57	01-09-2023
5	Contemporary Management of Acute Myeloid Leukemia	0	10.41	01-10-2024
6	Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy	0	11.16	01-06-2024
7	EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin	0	5	19-06-2026
8	Second Primary Malignant Neoplasms After T-Cell–Engaging Bispecific Antibody Therapy	0	7	18-06-2026
9	Study questions the value of intensive cardiac surveillance in cancer patients treated with anthracyclines	0	6.46	29-07-2026
10	Cardiac Risk After Heart-Sparing Breast Radiotherapy	0	5	02-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 8. Источник: archderm.jamanetwork.com.